REPL Replimune Group Inc
Company Analysis
Latest News
Replimune Group Inc Q1 2026 Earnings Preview: What Analysts Expect on July 02, 2026
Replimune Group is expected to report a fiscal loss of $0.73 per share on consensus revenue of $0.95 million, with the current stock price of $11.63 trading...
Replimune reports a wider fiscal 2026 net loss as the FDA accepts its RP1 application for review.
Replimune, a clinical-stage biotechnology company, reported no revenue for its fourth quarter or fiscal year 2026. The company posted a net loss of $73.7...
FDA Accepts Replimune's RP1 BLA Resubmission for Advanced Melanoma Treatment
Replimune Group announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of its Biologics License Application (BLA)...
Replimune Group Inc Q1 2026 Earnings Preview: What Analysts Expect on June 25, 2026
For the fiscal quarter ending March 2026, Replimune Group Inc is expected to report a consensus loss of $0.73 per share on zero revenue, with the current stock...
Biotech stocks rally, following FDA Commissioner Marty Makary’s resignation
FDA Commissioner Marty Makary resigned recently amid political pressure. Key leadership departures left top drug and biologics oversight positions to temporary...